# Single cEll pRofiling PErsistaNce To ImmuNothErapy

Source: https://onco.cc/trials/nct06680739/  
OnCo record `nct06680739` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab and tremelimumab in colorectal cancer, run by Vall d'Hebron Institute of Oncology, now recruiting.

## Summary

Single cEll pRofiling PErsistaNce To ImmuNothErapy is a phase 2, interventional study registered as NCT06680739 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 60 participants, started 2022-03-01 and due to reach its primary completion in 2032-07-01. Interventions recorded: Durvalumab; Tremelimumab. Conditions listed: Colorectal Cancer; Endometrial Cancer. Primary outcome: Evaluation of Objective Response Rate (ORR). Colorectal eligibility wording from the registry: ", Health Insurance Portability and Accountability Act in the US, European Union \[EU\] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations". Sites: Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SERPENTINE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06680739
- Phase: 2
- Setting: Single Cell Characterization of Persistent Cells Upon Treatment With Durvalumab (MEDI4736) With or Without Tremelimumab in MSS and MSI Colorectal and Endometrial Tumors: the SERPENTINE Clinical Trial
- Sponsor: Vall d'Hebron Institute of Oncology
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06680739: https://clinicaltrials.gov/study/NCT06680739

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06680739.json